In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Contrafect Corp (NASDAQ:CFRX) reported that Biotechnology Value Fund L P has picked up 2,443,720 of common stock as of 2017-07-28.
The acquisition brings the aggregate amount owned by Biotechnology Value Fund L P to a total of 2,443,720 representing a 3.2% in the company.
For those not familiar with the company, ContraFect is a clinical stage biotechnology company focused on discovering and developing therapeutic proteins and antibodies for life-threatening, drug-resistant infectious diseases, particularly those treated in hospital settings. An estimated 700,000 deaths worldwide each year are attributed to antimicrobial-resistant infections. Our lysin and monoclonal antibody platforms target conserved regions of bacteria or viruses (regions that are not prone to mutation). ContraFect’s initial product candidates include new agents to treat antibiotic-resistant infections such as MRSA (methicillin resistant Staph aureus) and influenza.
A glance at Contrafect Corp (NASDAQ:CFRX)’s key stats reveals a current market capitalization of 92.07M based on 73.66M shares outstanding and a price at last close of $1.25 per share.
Looking at insider activity, there are a few recent transactions worth noting.
Specifically, on 2017-07-25, Blech picked up 16,000 at a purchase price of $1.24 per share.This brings their total holding to 16,000 as of the date of the filing.
On the sell side, the most recent transaction saw Couto unload 2,872 shares at a sale price of $3.81. This brings their total holding to 0.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Contrafect Corp (NASDAQ:CFRX) as things move forward to see if its progress aligns with these transactions. Subscribe below and we’ll keep you on top of what’s happening before it moves markets.